Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ΔureC hly(+) Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis

Схожие документы

• Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant ΔureC hly(+) Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis
  по: Tchilian, Elma Z., et al.
  Опубликовано: (2009)
• Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis
  по: Gengenbacher, Martin, et al.
  Опубликовано: (2016)
• Recombinant BCG ΔureC hly+ Induces Superior Protection Over Parental BCG by Stimulating a Balanced Combination of Type 1 and Type 17 Cytokine Responses
  по: Desel, Christiane, et al.
  Опубликовано: (2011)
• Central Memory CD4(+) T Cells Are Responsible for the Recombinant Bacillus Calmette-Guérin ΔureC::hly Vaccine's Superior Protection Against Tuberculosis
  по: Vogelzang, Alexis, et al.
  Опубликовано: (2014)
• The Tuberculosis Vaccine Candidate Bacillus Calmette-Guérin ΔureC::hly Coexpressing Human Interleukin-7 or -18 Enhances Antigen-Specific T Cell Responses in Mice
  по: Rao, Martin, et al.
  Опубликовано: (2013)